ABSTRACT
Conclusion:
In our study, the positive effects of RRF on the treatment of anemia, phosphorus control and nutritional status in PD patients were shown.
Results:
One hundred and fifteen patients (52 females, 63 males; mean age: 56.0±13.2 years 20-83 years) receiving PD treatment were analyzed. The patients were divided into two groups according to presence or absence of RRF (n=75 and n=40, respectively). Patients with RRF had higher body weight (80±14 kg vs 68±13 kg; p<0.001), body mass index (29±5 kg/m² vs 25±5 kg/m²; p=0.009) and serum albumin level (3.6±0.5 vs 3.4±0.5 g/dL; p=0.027]. Patients with RRF had lower erythropoietin [29 (39%), vs. 34 (85%); p<0.001), sevelamer [17 (22.7%) vs 24 (60%); p<0.001] and calcimimetic [9 (12%) vs 14 (35%); p=0.007] usage rates and lower ferritin [159 (88-259) ng/mL vs 323 (170-495) ng/mL; p=0.001] level. rGFR was found to be positively correlated with Hb (r=0.274; p=0.017) and nPCR in patients with RRF (r=0.251; p=0.030).
Methods:
PD patients were retrospectively analyzed. Besides anthropometric measurements, biochemical measurements, such as residual glomerular filtration rate (rGFR), normalized protein catabolic rate (nPCR), hemoglobin (Hb), serum albumin, calcium, phosphorus, ferritin, parathormone and C-reactive protein levels were recorded.
Aim:
To evaluate the effects of residual renal function (RRF) on anemia treatment, phosphorus control and nutritional parameters in peritoneal dialysis (PD) patients.
References
1
Bargman JM, Thorpe KE, Churchill DN; CANUSA Peritoneal Dialysis Study Group. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001;12:2158-62.
2
Chandna SM, Farrington K. Residual renal function: considerations on its importance and preservation in dialysis patients. Semin Dial 2004;17:196-201.
3
Wang AY, Woo J, Wang M, et al. Imprortant differentiation of factors that predict outcome in peritoneal dialysis patients with different degrees of residual renal function. Nephrol Dial Transplant 2005;20:396-403.
4
Sikorska D, Pawlaczyk K, Olewicz-Gawlik A, et al. The importance of residual renal function in peritoneal dialysis. Int Urol Nephrol 2016;48:2101-8.
5
Rebić D, Matovinović MS, Rašić S, Kes P, Hamzić-Mehmedbašić A. The effect of preserved residıual renal function on left ventricular stucture in non-anuric peritoneal dialysis patients. Kidney Blood Press Res 2015;40:500-8.
6
Dervişoğlu E, Altun EA, Kalender B, et al. Effects of residual renal function on clinical and laboratory features of patients on continuous ambulatory peritoneal dialysis. Bantao Journal 2007;5:36-40.
7
Suda T, Hiroshige K, Ohta T, et al. The contribution of residual renal function to overall nutritional status in chronic hemodialysis patients. Nephrol Dial Transplant 2000;15:396-401.
8
Blake PG, Daugirdas JT. Adequacy of peritoneal dialysis and chronic peritoneal dialysis prescription. In: Daugirdas JT, Blake PG, Ing TS, editors. Handbook of Dialysis. 5th ed. Walters Kluwer; 2015. p. 454-71.
9
Paniagua R, Amato D, Vonesh E, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002;13:1307-20.
10
Wang AY, Wang M, Woo J, et al. A novel association between residual renal function and left ventricular hypertrophy in peritoneal dialysis patients. Kidney Int 2002;639-47.
11
Scanziani R, Dozio B, Bonforte G, Surian M. Residual renal function and nutritional parameters in CAPD. Adv Perit Dial 1995;11:106-9.
12
Jones MR. Etiology of severe malnutrition: results of an international cross-sectional study in continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 1994;23:412-20.
13
No authors listed. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol 1996;7:198-207.
14
Fung L, Pollock CA, Caterson RJ, et al. Dialysis adequacy and nutrition determine prognosis in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol 1996;7:737-44.
15
Wang AY, Wang M, Woo J, et al. Cardiac valve calcification as an important predictor for all cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol 2003;14:159-68.
16
Palmer SC, Hayen A, Macaskill P, et al. Serum Levels of Phosphorus, Parathyroid Hormone, and Calcium and Risks of Death and Cardiovascular Disease in Individuals With Chronic Kidney Disease. JAMA 2011;305:1119-27.
17
Winchester JF, Rotellar C, Goggins M, Robino D, Rakowski TA, Argy WP. Calcium and phosphate balance in dialysis patients. Kidney Int Suppl 1993;41:174-8.
18
Wang AY, Woo J, Sea MM, Law MC, Lui SF, Li PK. Hyperphosphatemia in chinese peritoneal dialysis patients with and without residual kidney function: what are the implications? Am J Kidney Dis 2004;43:712-20.
19
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009:76:113:1-130.
20
Stompór T. Coronary artery calcification in chronic kidney disease. An Update. World J Cardiol 2014;6:115-29.
21
Tentori F, Blayney MJ, Albert JM, et al. Mortality Risk for Dialysis Patients With Different Levels of Serum Calcium, Phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008;52:519-30.
22
Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 2011;6:913-21.
23
Verheyen N, Pilz S, Eller K, et al. Cinacalcet hydrochloride for the treatment of hyperparathyroidism Expert Opin. Pharmacother 2013;14:793-806.
24
Pérez-Ricart A, Galicia-Basart M, Alcalde-Rodrigo M, et al. Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis. PLoS One 2016;11:e0161527.
25
Altunören O, Güngör Ö, Eren N, et al. The Efficay of Cinacalcet in the Treatment of Hyperparathyroidism in Turkish Hemodialysis Patient Population. Turkish J Nephrol 2016;25:192-8.
26
Menon MK, Naimark DM, Bargman JM, Vas SI, Oreopoulos DG. Long-term blood pressure control in a cohort of peritoneal dialysis patients and its association with residual renal function. Nephrol Dial Transplant 2001;16:2207-13.
27
Ateş K, Ateş A, Ekmekçi Y, Nergizoğlu G. The time course of serum C-reactive protein is more predictive of mortality than its baseline level in peritoneal dialysis patients. Perit Dial Int 2005;25:256-68.
28
Lameire N. Cardiovascular risk factors and blood pressure control in continuous ambulatory peritoneal dialysis. Perit Dial Int 1993;13(Suppl 2):394-5.
29
Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link? Kidney Int 2001;59:407-14.
30
Noh H, Lee SW, Kang SW, Shin SK, Choi KH, Lee HY, Han DS. Serum C-reactive protein: a predictor of mortality in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1998;18:387-94.
31
Fein PA, Fazil I, Rafiq MA, et al. Relationship of peritoneal transport rate and dialysis adequacy with inflammation in peritoneal dialysis patients. Adv Perit Dial 2006;22:2-6.
32
Shang D, Xie Q, Shang B, et al. Hyperphosphatemia and hs-CRP Initiate the Coronary Artery Calcification in Peritoneal Dialysis Patients. Biomed Res Int 2017;2017:2520510.